Longevity Health(XAGE.US)

Company Encyclopedia
View More
name
Longevity Health
XAGE.US
Longevity Health Holdings, Inc., a bio-aesthetics company, focuses on developing, manufacturing, and marketing cosmetic skincare and haircare products. The company utilizes Carmell Secretome and Elevai Exosomes to support skin and hair health. Its Carmell Secretome consists of growth factors, proteins, and peptides extracted from allogeneic human platelets; and Elevai Exosomes constains growth factors, cytokines, peptides, and other small molecules involved in the body’s natural healing process. The company also develops a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products.
1.899 T
XAGE.USMarket value -Rank by Market Cap -/-

Financial Score

12/01/2026 Update
C
BiotechnologyIndustry
Industry Ranking175/398
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE142.66%A
    • Profit Margin-393.63%E
    • Gross Margin54.29%B
  • Growth ScoreA
    • Revenue YoY4337.74%A
    • Net Profit YoY8.90%C
    • Total Assets YoY35.10%A
    • Net Assets YoY2.15%C
  • Cash ScoreB
    • Cash Flow Margin-25.40%D
    • OCF YoY4337.74%A
  • Operating ScoreC
    • Turnover0.51C
  • Debt ScoreE
    • Gearing Ratio220.56%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Longevity Health | 10-Q: FY2025 Q3 Revenue: USD 425.86 K

    LB filings·
    US
    XAGE
    0.00%
    LB filings·
    US
    XAGE
    0.00%

    Longevity Health Holdings Updates Merger Terms with True Health and TMG

    Longevity Health Holdings Inc. has updated its merger agreement with True Health Inc. and Truehealth Management Group LLC. The new terms specify that the number of common shares to be issued will be based on $59 million divided by the lower of the company's market price or $3.00 per share, with potential adjustments for stock splits. An additional $20 million in shares may be issued as earnout consideration, calculated similarly. The market price will be determined by the volume weighted average closing price over the 15 trading days before the merger's effective date.

    Reuters·
    US
    XAGE
    0.00%
    Reuters·
    US
    XAGE
    0.00%

    Longevity Health Holdings Inc. Delisted from Nasdaq, Moves to OTC Markets Following Rule Violation

    Longevity Health Holdings Inc. has been delisted from the Nasdaq due to a violation of Listing Rule 5550(b)(2) and will now trade on OTC Markets starting September 12, 2025. The company plans to continue its operations and pursue a merger with True Health Inc., aiming to relist the merged entity on Nasdaq. Despite the delisting, Longevity Health will maintain compliance with reporting requirements under the Securities Exchange Act of 1934.

    Reuters·
    US
    XAGE
    0.00%
    Reuters·
    US
    XAGE
    0.00%

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    In Tuesday's after-market session, several health care stocks saw significant movements. Propanc Biopharma (PPCB) shares surged 15.8% to $4.25, with a market value of $67.9 million. enVVeno Medical (NVNO) rose 14.04% to $4.75, valued at $87.5 million. Adicet Bio (ACET) increased by 9.77% to $0.72, with a market cap of $60.3 million. Chemomab Therapeutics (CMMB) shares climbed 9.67% to $1.02, valued at $17.7 million. Longevity Health Holdings (XAGE) rose 9.63% to $2.83, with a market cap of $3.6 million. BioLine Rx (BLRX) increased by 6.68% to $3.99, valued at $14.2 million. The Q2 earnings report for some of these companies was released three days ago.

    Benzinga·
    US
    PPCB
    -3.79%
    US
    CMMB
    -0.56%
    US
    XAGE
    0.00%
    Benzinga·
    US
    PPCB
    -3.79%
    US
    CMMB
    -0.56%
    US
    XAGE
    0.00%

    US Stock Market Update: Longevity Health up 9.79%

    Longevity Health rose 9.79%; AbbVie rose 0.65%, with a transaction volume of USD 510 million; Precigen rose 59.19%, with a transaction volume of USD 488 million; Regeneron Pharmaceuticals rose 2.42%, with a transaction volume of USD 423 million; Amgen rose 1.80%, with a market value of USD 159.1 billion

    Tracking Unusual Activity·
    US
    XAGE
    0.00%
    Tracking Unusual Activity·
    US
    XAGE
    0.00%
    © 2026 Longbridge｜Disclaimer